Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.

A Novel Partial MHC Class II Construct, DRmQ, Inhibits Central and Peripheral Inflammatory Responses to Promote Neuroprotection in Experimental Stroke.

Lee JY, Castelli V, Bonsack B, Coats AB, Navarro-Torres L, Garcia-Sanchez J, Kingsbury C, Nguyen H, Vandenbark AA, Meza-Romero R, Offner H, Borlongan CV.

Transl Stroke Res. 2019 Dec 3. doi: 10.1007/s12975-019-00756-1. [Epub ahead of print]

PMID:
31797249
2.

Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE.

Seifert HA, Gerstner G, Kent G, Vandenbark AA, Offner H.

J Neuroinflammation. 2019 Oct 29;16(1):195. doi: 10.1186/s12974-019-1588-z.

3.

Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke.

Seifert HA, Zhu W, Vandenbark AA, Alkayed NJ, Offner H.

Metab Brain Dis. 2019 Dec;34(6):1705-1712. doi: 10.1007/s11011-019-00476-3. Epub 2019 Aug 13.

4.

A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury.

Vandenbark AA, Meza-Romero R, Benedek G, Offner H.

J Neuroinflammation. 2019 Jan 23;16(1):14. doi: 10.1186/s12974-018-1393-0. Review.

5.

Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.

Meza-Romero R, Benedek G, Gerstner G, Kent G, Nguyen H, Offner H, Vandenbark AA.

Metab Brain Dis. 2019 Feb;34(1):153-164. doi: 10.1007/s11011-018-0331-2. Epub 2018 Oct 23.

6.

Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells.

Seifert HA, Benedek G, Nguyen H, Gerstner G, Zhang Y, Kent G, Vandenbark AA, Bernhagen J, Offner H.

Metab Brain Dis. 2018 Oct;33(5):1599-1607. doi: 10.1007/s11011-018-0266-7. Epub 2018 Jun 18.

7.

Regulatory B cells in experimental stroke.

Seifert HA, Vandenbark AA, Offner H.

Immunology. 2018 Jun;154(2):169-177. doi: 10.1111/imm.12887. Epub 2018 Feb 5. Review.

8.

MIF and D-DT are potential disease severity modifiers in male MS subjects.

Benedek G, Meza-Romero R, Jordan K, Zhang Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, Du X, Sreih A, Leng L, Wiedrick J, Caillier SJ, Offner H, Oksenberg JR, Yadav V, Bourdette D, Bucala R, Vandenbark AA.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8421-E8429. doi: 10.1073/pnas.1712288114. Epub 2017 Sep 18.

9.

Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells.

Benedek G, Zhang J, Nguyen H, Kent G, Seifert HA, Davin S, Stauffer P, Vandenbark AA, Karstens L, Asquith M, Offner H.

J Neuroimmunol. 2017 Sep 15;310:51-59. doi: 10.1016/j.jneuroim.2017.06.007. Epub 2017 Jun 21.

10.

Estrogen protects both sexes against EAE by promoting common regulatory cell subtypes independent of endogenous estrogen.

Seifert HA, Benedek G, Nguyen H, Kent G, Vandenbark AA, Offner H.

Metab Brain Dis. 2017 Oct;32(5):1747-1754. doi: 10.1007/s11011-017-0063-8. Epub 2017 Jul 8.

11.

Sex differences in regulatory cells in experimental stroke.

Seifert HA, Benedek G, Liang J, Nguyen H, Kent G, Vandenbark AA, Saugstad JA, Offner H.

Cell Immunol. 2017 Aug;318:49-54. doi: 10.1016/j.cellimm.2017.06.003. Epub 2017 Jun 8.

12.

Sex-dependent treatment of chronic EAE with partial MHC class II constructs.

Benedek G, Chaudhary P, Meza-Romero R, Calkins E, Kent G, Offner H, Bourdette D, Vandenbark AA.

J Neuroinflammation. 2017 May 6;14(1):100. doi: 10.1186/s12974-017-0873-y.

13.

DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.

Yang L, Liu Z, Ren H, Zhang L, Gao S, Ren L, Chai Z, Meza-Romero R, Benedek G, Vandenbark AA, Offner H, Li M.

Metab Brain Dis. 2017 Oct;32(5):1395-1402. doi: 10.1007/s11011-017-9991-6. Epub 2017 Mar 16.

14.

Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice.

Benedek G, Zhang J, Nguyen H, Kent G, Seifert H, Vandenbark AA, Offner H.

J Neuroimmunol. 2017 Apr 15;305:59-67. doi: 10.1016/j.jneuroim.2016.12.018. Epub 2017 Jan 28.

15.

DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.

Wang J, Ye Q, Xu J, Benedek G, Zhang H, Yang Y, Liu H, Meza-Romero R, Vandenbark AA, Offner H, Gao Y.

Transl Stroke Res. 2017 Jun;8(3):284-293. doi: 10.1007/s12975-016-0514-2. Epub 2016 Dec 17.

16.

Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.

Yang L, Kong Y, Ren H, Li M, Wei CJ, Shi E, Jin WN, Hao J, Vandenbark AA, Offner H.

Neurochem Int. 2017 Jul;107:148-155. doi: 10.1016/j.neuint.2016.11.007. Epub 2016 Nov 21.

17.

Partial MHC class II constructs as novel immunomodulatory therapy for stroke.

Benedek G, Vandenbark AA, Alkayed NJ, Offner H.

Neurochem Int. 2017 Jul;107:138-147. doi: 10.1016/j.neuint.2016.10.007. Epub 2016 Oct 31. Review.

18.

Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74.

Meza-Romero R, Benedek G, Jordan K, Leng L, Pantouris G, Lolis E, Bucala R, Vandenbark AA.

Cytokine. 2016 Dec;88:62-70. doi: 10.1016/j.cyto.2016.08.024. Epub 2016 Aug 27.

19.

Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis.

Benedek G, Zhang J, Bodhankar S, Nguyen H, Kent G, Jordan K, Manning D, Vandenbark AA, Offner H.

J Neuroimmunol. 2016 Apr 15;293:45-53. doi: 10.1016/j.jneuroim.2016.02.009. Epub 2016 Feb 13.

20.

Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.

Meza-Romero R, Benedek G, Leng L, Bucala R, Vandenbark AA.

Metab Brain Dis. 2016 Apr;31(2):249-55. doi: 10.1007/s11011-016-9798-x. Epub 2016 Feb 6.

21.

PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.

Bodhankar S, Chen Y, Lapato A, Dotson AL, Wang J, Vandenbark AA, Saugstad JA, Offner H.

Stroke. 2015 Oct;46(10):2926-34. doi: 10.1161/STROKEAHA.115.010592. Epub 2015 Aug 25.

22.

Role for microglia in sex differences after ischemic stroke: importance of M2.

Bodhankar S, Lapato A, Chen Y, Vandenbark AA, Saugstad JA, Offner H.

Metab Brain Dis. 2015 Dec;30(6):1515-29. doi: 10.1007/s11011-015-9714-9. Epub 2015 Aug 6.

23.

IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice.

Zhang J, Benedek G, Bodhankar S, Lapato A, Vandenbark AA, Offner H.

J Neuroimmunol. 2015 Aug 15;285:129-36. doi: 10.1016/j.jneuroim.2015.06.002. Epub 2015 Jun 11.

24.

HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.

Benedek G, Meza-Romero R, Jordan K, Keenlyside L, Offner H, Vandenbark AA.

J Neuroinflammation. 2015 Jun 24;12:123. doi: 10.1186/s12974-015-0342-4.

25.

Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice.

Zhang J, Lapato A, Bodhankar S, Vandenbark AA, Offner H.

Metab Brain Dis. 2015 Oct;30(5):1117-27. doi: 10.1007/s11011-015-9661-5. Epub 2015 Mar 18.

26.

Regulatory CD8(+)CD122 (+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells.

Bodhankar S, Chen Y, Lapato A, Vandenbark AA, Murphy SJ, Saugstad JA, Offner H.

Metab Brain Dis. 2015 Aug;30(4):911-924. doi: 10.1007/s11011-014-9639-8. Epub 2014 Dec 25.

27.

The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis.

Benedek G, Meza-Romero R, Bourdette D, Vandenbark AA.

Metab Brain Dis. 2015 Aug;30(4):877-84. doi: 10.1007/s11011-014-9634-0. Epub 2014 Dec 12. Review.

28.

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.

Bodhankar S, Chen Y, Lapato A, Vandenbark AA, Murphy SJ, Offner H.

Front Cell Neurosci. 2014 Aug 11;8:228. doi: 10.3389/fncel.2014.00228. eCollection 2014.

29.

Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke.

Pan J, Palmateer J, Schallert T, Hart M, Pandya A, Vandenbark AA, Offner H, Hurn PD.

Transl Stroke Res. 2014 Oct;5(5):577-85. doi: 10.1007/s12975-014-0345-y. Epub 2014 May 18.

30.

Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection.

Huckans M, Fuller BE, Olavarria H, Sasaki AW, Chang M, Flora KD, Kolessar M, Kriz D, Anderson JR, Vandenbark AA, Loftis JM.

Brain Behav. 2014 Mar;4(2):123-42. doi: 10.1002/brb3.200. Epub 2013 Dec 29.

31.

HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.

Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA.

J Immunol. 2014 May 1;192(9):4164-73. doi: 10.4049/jimmunol.1303118. Epub 2014 Mar 28.

32.

Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice.

Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H.

Metab Brain Dis. 2014 Mar;29(1):59-73. doi: 10.1007/s11011-013-9474-3. Epub 2013 Dec 28.

33.

Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice.

Banerjee A, Wang J, Bodhankar S, Vandenbark AA, Murphy SJ, Offner H.

Transl Stroke Res. 2013 Oct;4(5):554-63.

34.

A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.

Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, Vandenbark AA, Alkayed NJ, Offner H.

Metab Brain Dis. 2014 Mar;29(1):37-45. Erratum in: Metab Brain Dis. 2014 Sep;29(3):885.

35.

PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.

Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H.

J Neuroinflammation. 2013 Sep 9;10:111. doi: 10.1186/1742-2094-10-111.

36.

PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE.

Bodhankar S, Galipeau D, Vandenbark AA, Offner H.

J Clin Cell Immunol. 2013 May 6;4(3):143.

37.

IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke.

Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H.

Metab Brain Dis. 2013 Sep;28(3):375-86. doi: 10.1007/s11011-013-9413-3. Epub 2013 May 3.

38.

Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.

Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows GG, Bourdette D, Offner H, Bucala R, Vandenbark AA.

Eur J Immunol. 2013 May;43(5):1309-21. doi: 10.1002/eji.201243162. Epub 2013 Apr 10.

39.

Partial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addiction.

Loftis JM, Wilhelm CJ, Vandenbark AA, Huckans M.

PLoS One. 2013;8(2):e56306. doi: 10.1371/journal.pone.0056306. Epub 2013 Feb 27.

40.

The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN.

Ooi JD, Chang J, O'Sullivan KM, Pedchenko V, Hudson BG, Vandenbark AA, Fugger L, Holdsworth SR, Kitching AR.

J Am Soc Nephrol. 2013 Feb;24(3):419-31. doi: 10.1681/ASN.2012070705. Epub 2013 Feb 14.

42.

A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.

Vandenbark AA, Meza-Romero R, Benedek G, Andrew S, Huan J, Chou YK, Buenafe AC, Dahan R, Reiter Y, Mooney JL, Offner H, Burrows GG.

J Autoimmun. 2013 Feb;40:96-110. doi: 10.1016/j.jaut.2012.08.004. Epub 2012 Sep 29.

43.

Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice.

Chen Y, Bodhankar S, Murphy SJ, Vandenbark AA, Alkayed NJ, Offner H.

Metab Brain Dis. 2012 Dec;27(4):487-93. doi: 10.1007/s11011-012-9317-7. Epub 2012 May 18.

44.

Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.

Yadav V, Bourdette DN, Bowen JD, Lynch SG, Mattson D, Preiningerova J, Bever CT Jr, Simon J, Goldstein A, Burrows GG, Offner H, Ferro AJ, Vandenbark AA.

Autoimmune Dis. 2012;2012:954739. doi: 10.1155/2012/954739. Epub 2012 Apr 5.

45.

Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis.

Burrows GG, Meza-Romero R, Huan J, Sinha S, Mooney JL, Vandenbark AA, Offner H.

Metab Brain Dis. 2012 Jun;27(2):143-9. doi: 10.1007/s11011-012-9289-7. Epub 2012 Mar 7.

46.

Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.

Adamus G, Brown L, Andrew S, Meza-Romero R, Burrows GG, Vandenbark AA.

Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):406-12. doi: 10.1167/iovs.11-8419.

47.

Regulatory T cells play a role in T-cell receptor CDR2 peptide regulation of experimental autoimmune encephalomyelitis.

Buenafe AC, Andrew S, Offner H, Vandenbark AA.

Immunology. 2012 Feb;135(2):168-79. doi: 10.1111/j.1365-2567.2011.03531.x.

48.

Contribution of GPR30 for 1,25 dihydroxyvitamin D₃ protection in EAE.

Subramanian S, Miller LM, Grafe MR, Vandenbark AA, Offner H.

Metab Brain Dis. 2012 Mar;27(1):29-35. doi: 10.1007/s11011-011-9266-6. Epub 2011 Oct 13.

PMID:
21994003
49.

Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity.

Ren X, Akiyoshi K, Grafe MR, Vandenbark AA, Hurn PD, Herson PS, Offner H.

Metab Brain Dis. 2012 Mar;27(1):7-15. doi: 10.1007/s11011-011-9267-5. Epub 2011 Oct 12.

50.

Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia.

Akiyoshi K, Dziennis S, Palmateer J, Ren X, Vandenbark AA, Offner H, Herson PS, Hurn PD.

Transl Stroke Res. 2011 Sep 1;2(3):404-10. doi: 10.1007/s12975-011-0085-1.

Supplemental Content

Loading ...
Support Center